| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Francesca Mancini, Marina Naldi, Vanni Cavrini, Vincenza Andrisan. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Analytical and bioanalytical chemistry. vol 388. issue 5-6. 2007-08-20. PMID:17541560. |
therefore, in order to select new leads endowed with multifunctional activities, drugs for alzheimer's disease (ad) - potent acetylcholinesterase (ache) inhibitors - were tested for bace-1 inhibition using the proposed validated assays. |
2007-08-20 |
2023-08-12 |
Not clear |
| María-Salud García-Ayllón, María-Ximena Silveyra, Niels Andreasen, Stephen Brimijoin, Kaj Blennow, Javier Sáez-Valer. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. Journal of neurochemistry. vol 101. issue 6. 2007-08-16. PMID:17326766. |
we analyzed whether donepezil differently influences acetylcholinesterase (ache) variants from cerebrospinal fluid (csf) in patients with alzheimer's disease (ad) after long-term treatment. |
2007-08-16 |
2023-08-12 |
Not clear |
| Iljung Lee, Yearn Seong Choe, Eun Kyoung Ryu, Byoung Wook Choi, Joon Young Choi, Yong Choi, Kyung-Han Lee, Byung-Tae Ki. Synthesis and evaluation of radioiodine-labelled CP-118,954 for the in-vivo imaging of acetylcholinesterase. Nuclear medicine communications. vol 28. issue 7. 2007-08-08. PMID:17538398. |
alzheimer's disease (ad) is characterized by reduced acetylcholinesterase (ache) activity in the post-mortem tissues of ad patients. |
2007-08-08 |
2023-08-12 |
Not clear |
| Maibritt B Andersen, Thomas Werge, Anders Fink-Jense. The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. The Journal of pharmacology and experimental therapeutics. vol 321. issue 3. 2007-07-30. PMID:17374745. |
centrally acting selective muscarinic receptor agonists are currently not available for clinical use, but acetylcholinesterase (ache) inhibitors, which indirectly stimulate achr by blocking the breakdown of acetylcholine by ache, are widely used in the clinic against alzheimer's disease. |
2007-07-30 |
2023-08-12 |
monkey |
| Maibritt B Andersen, Thomas Werge, Anders Fink-Jense. The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. The Journal of pharmacology and experimental therapeutics. vol 321. issue 3. 2007-07-30. PMID:17374745. |
ache inhibitors have been reported to exhibit antipsychotic efficacy in alzheimer's disease patients, and these compounds have also been investigated as adjunctive treatment to antipsychotic medication in schizophrenic patients with varying results. |
2007-07-30 |
2023-08-12 |
monkey |
| Julia Roensch, Milita Crisby, Agneta Nordberg, Yan Xiao, Lan-Jiang Zhang, Zhi-Zhong Gua. Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochemistry international. vol 50. issue 6. 2007-07-26. PMID:17412455. |
in order to reveal the neuroprotective effects of statins that could be of interest for the prevention and treatment of alzheimer's disease (ad), we investigated the expression of nicotinic acetylcholine receptors (nachrs) detected by rt-pcr, the activity of acetylcholinesterase (ache) and butyrylcholinesterase (buche) by colorimetric determination, and the levels of the alpha-form of secreted beta-amyloid precursor protein (alphaapps) by western blotting in neuroblastoma (sh-sy5y) cells exposed to lovastatin, atorvastatin, rosuvastatin and simvastatin, respectively. |
2007-07-26 |
2023-08-12 |
Not clear |
| Efrat Groner, Yacov Ashani, Donna Schorer-Apelbaum, Jeffrey Sterling, Yaacov Herzig, Marta Weinstoc. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Molecular pharmacology. vol 71. issue 6. 2007-07-18. PMID:17347320. |
controlled inhibition of brain acetyl- and butyrylcholinesterases (ache and bche, respectively) and of monoamine oxidase-b (mao-b) may slow neurodegeneration in alzheimer's and parkinson's diseases. |
2007-07-18 |
2023-08-12 |
human |
| C Eggers, B Szelies, B Bauer, K Wienhard, H Schröder, K Herholz, W-D Heis. Imaging of acetylcholine esterase activity in brainstem nuclei involved in regulation of sleep and wakefulness. European journal of neurology. vol 14. issue 6. 2007-07-10. PMID:17539952. |
positron emission tomography with 11c-n-methyl-4-piperidyl-acetate (mp4a) was applied in eight healthy volunteers and two patients with mild alzheimer's disease (ad) to assess acetylcholine esterase (ache) activity in magnetic resonance imaging-identified brainstem nuclei. |
2007-07-10 |
2023-08-12 |
human |
| Byoung Wook Choi, Geonseek Ryu, Soo Hee Park, Eun Sook Kim, Jongheon Shin, Seok Seon Roh, Hyeon Cheol Shin, Bong Ho Le. Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer's disease therapy. Phytotherapy research : PTR. vol 21. issue 5. 2007-07-09. PMID:17236179. |
however, for butyrylcholinesterase (buche), a new target for the treatment of alzheimer's disease (ad), compound 1 showed particularly potent inhibitory activity (ic(50) 26 nm), which is 1000-fold greater than for ache. |
2007-07-09 |
2023-08-12 |
Not clear |
| Pulok K Mukherjee, Venkatesan Kumar, Mainak Mal, Peter J Houghto. Acetylcholinesterase inhibitors from plants. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 14. issue 4. 2007-05-31. PMID:17346955. |
inhibition of acetylcholinesterase (ache), the key enzyme in the breakdown of acetylcholine, is considered as a promising strategy for the treatment of neurological disorders such as alzheimer's disease, senile dementia, ataxia and myasthenia gravis. |
2007-05-31 |
2023-08-12 |
Not clear |
| Tadanobu Utsuki, Nao Uchimura, Mitsuru Irikura, Hiroshi Moriuchi, Harold W Holloway, Qian-Sheng Yu, Edward L Spangler, Jacek Mamczarz, Donald K Ingram, Tetsumi Irie, Nigel H Grei. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. The Journal of pharmacology and experimental therapeutics. vol 321. issue 1. 2007-05-14. PMID:17255466. |
phenserine (ps) was designed as a selective acetylcholinesterase (ache) inhibitor, with a tartrate form (pst) for oral administration in mild to moderate alzheimer's disease (ad). |
2007-05-14 |
2023-08-12 |
mouse |
| Kristin Huse Haug, Trond Myhrer, Frode Fonnu. The combination of donepezil and procyclidine protects against soman-induced seizures in rats. Toxicology and applied pharmacology. vol 220. issue 2. 2007-05-14. PMID:17289099. |
in this study, we have evaluated donepezil hydrochloride, a partial reversible inhibitor of acetylcholinesterase (ache) clinically used for treating alzheimer's disease, in combination with procyclidine, used in treatment of parkinson's disease and schizophrenia, as prophylaxis against intoxication by the nerve agent soman. |
2007-05-14 |
2023-08-12 |
rat |
| M Dumont, R Lalonde, J-F Ghersi-Egea, K Fukuchi, C Straziell. Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 9. 2007-05-02. PMID:16362638. |
the ache activity of tg13592 mice was altered in several regions implicated in the functional loop of regulation between septum and hippocampus, vulnerable in alzheimer pathology and critically involved in cognitive functions. |
2007-05-02 |
2023-08-12 |
mouse |
| Carsten Eggers, Karl Herholz, Elke Kalbe, Wolf-Dieter Heis. Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. Neuroscience letters. vol 408. issue 1. 2007-04-03. PMID:16996687. |
positron emission tomography (pet) studies have demonstrated reduced acetylcholine esterase (ache) activity as an indicator of cholinergic impairment, which is a main pathogenic process in alzheimer's disease (ad). |
2007-04-03 |
2023-08-12 |
human |
| Seok-Jong Suh, Byung-Soo Koo, Un-Ho Jin, Moon-Je Hwang, In-Seon Lee, Cheorl-Ho Ki. Pharmacological characterization of orally active cholinesterase inhibitory activity of Prunus persica L. Batsch in rats. Journal of molecular neuroscience : MN. vol 29. issue 2. 2007-04-02. PMID:16954599. |
prunus persica l. batsch water extract (ppe) is a potent acetylcholinesterase (ache) inhibitor screened for the treatment of alzheimer's disease. |
2007-04-02 |
2023-08-12 |
rat |
| Juan Li, Hong Huang, Jean-Marc Miezan Ezoulin, Xiao-Ling Gao, France Massicot, Chang-Zhi Dong, Françoise Heymans, Hong-Zhuan Che. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. The international journal of neuropsychopharmacology. vol 10. issue 1. 2007-03-30. PMID:16426477. |
taken together, these results demonstrate that pms777 possesses dual activities for paf receptor antagonism and ache inhibition, suggesting that this compound may be a promising lead compound for further investigation related to the treatment for alzheimer's disease. |
2007-03-30 |
2023-08-12 |
mouse |
| Sylvie Chouinard, Emmanuel Stip, Julie Poulin, Jean-Pierre Melun, Roger Godbout, François Guillem, Henri Cohe. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Current medical research and opinion. vol 23. issue 3. 2007-03-30. PMID:17355738. |
acetylcholinesterase (ache) inhibitors, such as rivastigmine, have been shown to improve cognition in other disorders, particularly alzheimer's disease. |
2007-03-30 |
2023-08-12 |
Not clear |
| Ana Castro, Ana Martine. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Current pharmaceutical design. vol 12. issue 33. 2007-03-26. PMID:17105433. |
this review highlights the collection of several compounds with an outstanding profile against ache-induced amyloid aggregation and potent ache inhibitory activity, indicating the possibility of targeting abeta through the inhibition of ache and reveals the emergence of a new generation of ache inhibitors aiming to be excellent candidate drugs for the future cure of alzheimer's disease. |
2007-03-26 |
2023-08-12 |
Not clear |
| Lisa M Eubanks, Claude J Rogers, Albert E Beuscher, George F Koob, Arthur J Olson, Tobin J Dickerson, Kim D Jand. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular pharmaceutics. vol 3. issue 6. 2007-03-26. PMID:17140265. |
here, we demonstrate that the active component of marijuana, delta9-tetrahydrocannabinol (thc), competitively inhibits the enzyme acetylcholinesterase (ache) as well as prevents ache-induced amyloid beta-peptide (abeta) aggregation, the key pathological marker of alzheimer's disease. |
2007-03-26 |
2023-08-12 |
Not clear |
| María del Monte-Millán, Esther García-Palomero, Rita Valenzuela, Paola Usán, Celia de Austria, Pilar Muñoz-Ruiz, Laura Rubio, Isabel Dorronsoro, Ana Martínez, Miguel Medin. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. Journal of molecular neuroscience : MN. vol 30. issue 1-2. 2007-02-23. PMID:17192640. |
the therapeutic potential of acetylcholinesterase (ache) inhibitors has been strengthened recently by evidence showing that besides their role in cognitive function, they might contribute to slow down the neurodegeneration in alzheimer's disease (ad) patients. |
2007-02-23 |
2023-08-12 |
Not clear |